Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Daniel Welch
Age : 64
Public asset : 6,403,830 USD
Country of residence : Unknown
Linked companies : Seagen Inc. - Structure Therapeutics Inc. - Ultragenyx Pharmaceutical Inc. - Nuvation Bio Inc.

Biography of Daniel Welch 
Daniel G. Welch is a businessperson who has been at the head of 8 different companies and holds the position of Non-Executive Chairman for Ultragenyx Pharmaceutical, Inc., Executive Chairman at InCarda Therapeutics, Inc. and Chairman at Nuvation Bio, Inc., Chairman of Nuvation Bio Operating Co., Inc. (a subsidiary of Nuvation Bio, Inc.). He is also on the board of Seagen Inc., Intercept Pharmaceuticals, Inc. and Levo Therapeutics, Inc. (former Executive Chairman). In the past Mr. Welch held the position of Executive Partner at Sofinnova Investments, Inc., Chairman & Chief Executive Officer at Triangle Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer for InterMune, Inc., Chairman at AveXis, Inc., President-Biopharmaceuticals Division at Elan Corp. Plc, Principal at Adria Laboratories, Vice President-Worldwide Marketing at Sterling Winthrop, Inc. and Chief Operating Officer & Executive Vice President for Sanofi-Synthelabo, Inc. Daniel G. Welch received an undergraduate degree from the University of Miami and an MBA from The University of North Carolina at Charlotte.


Current positions of Daniel Welch 
Holdings of Daniel Welch 
Daniel Welch : Personal Network 
Most Read News 
01/25Musk says China rivals 'work hardest, smartest'
RE
01/27Wood's ARK Innovation Fund on pace for best month ever as battered stocks surge
RE
01/26LVMH's Arnault brushes off succession question
RE
01/26Bill Ackman says Hindenburg's report on Adani Group 'highly credible'
RE
02/02Billionaire Cohen builds stake in Nordstrom, urges board shakeup
RE
02/03Exclusive-BlackRock sustainability chief Bodnar to join Bezos Earth Fund - memo
RE
02/03U.S. jury finds Tesla and Musk not liable in case over take-private tweet
RE
02/03SoftBank Q3 seen under pressure from tech weakness, Arm IPO eyed
RE
02/01Sony Group CFO Totoki to succeed Yoshida as president - Nikkei
RE
01/31Italy considers replacements for Starace as Enel CEO, sources say
RE
More news


© 2023 People and Ownership :   
Daniel Welch : Connections 


Latest news about Daniel Welch 
2021Nuvation Bio, Inc. completed the acquisition of Panacea Acquisition Corp. in a reverse merger transaction.
CI
2020Nuvation Bio, Inc. Announces Management Changes
CI
2020Nuvation Bio, Inc. entered into an agreement to acquire Panacea Acquisition Corp. for $1.7 billion in a reverse merger transaction.
CI
2020Transcript : Ultragenyx Pharmaceutical Inc. - Shareholder/Analyst Call
CI
2019Transcript : Ultragenyx Pharmaceutical Inc. - Shareholder/Analyst Call
CI
2018Transcript : Ultragenyx Pharmaceutical Inc. - Shareholder/Analyst Call
CI
2017Transcript : Ultragenyx Pharmaceutical Inc. - Shareholder/Analyst Call
CI
More news